cfDNA Methylation for Liver Cancer Recurrence Detection

Condition(s) studied

Investigational drug(s) / intervention(s)

plasma GNB4 and Riplet genes methylation detection: Liver cancer patients undergo methylation testing at different follow-up time points after treatment

Study summary

Through follow-up testing of patients with primary liver cancer who underwent hepatectomy, liver transplantation, ablation therapy, or transarterial chemoembolization (TACE), a blinded comparative trial was conducted at each monitoring site. This trial evaluated the combined methylation detection kit for GNB4 and Riplet genes (fluorescent PCR method) against the clinical reference standard (defined as the physician's comprehensive diagnosis based on clinical guidelines and other criteria). The study evaluated the clinical performance of the assay in diagnosing primary liver cancer recurrence and validated the clinical efficacy of methylation detection kits for monitoring recurrence after primary liver cancer treatment.

Eligibility

Primary outcome measure(s)

• sensitivity — Through study completion, an average of 1 year
• specificity — Through study completion, an average of 1 year

Trial sites (1)

Other trials for the same condition